GlassScriptPhysician profile
Blessing Nwaneri
NPI 1184272403
$3,208.25
in general payments reported to CMS, 2019-2025
23 companies · $953 in 2025
The $953 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $362 · 2023: $76.32 · 2024: $1,116 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.27 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $361.64 | 2021-2025 | Wegovy, Ozempic |
| Biodelivery Sciences International, INC. | $234.43 | 2021 | |
| Scilex Pharmaceuticals INC. | $225.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $200.00 | 2024-2025 | Arexvy |
| Teva Pharmaceuticals USA, INC. | $194.47 | 2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $184.91 | 2024-2025 | Xarelto, Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.92 | 2024 | Jardiance |
| Medtronic, INC. | $103.77 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $103.72 | 2024 | Rexulti |
| Abbott Laboratories | $101.77 | 2024 | Freestyle Libre 3 |
| Lexicon Pharmaceuticals, INC. | $99.44 | 2024 | Inpefa |
| Daiichi Sankyo INC. | $97.79 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.75 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $95.40 | 2024 | |
| Collegium Pharmaceutical, INC. | $84.07 | 2021 | |
| Xeris Pharmaceuticals, INC. | $82.68 | 2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $76.32 | 2023 | Camzyos |
| Orexo US, INC. | $50.01 | 2021-2022 | |
| Horizon Therapeutics Plc | $36.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $15.90 | 2022 | |
| Redhill Biopharma INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blessing Nwaneri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.